Envoy Medical - Class A (COCH) closed at $6.70 on November 19, 2026, down 0.4% from the previous close, on volume of 30,821 shares (30-day average 76,099).
Data as of November 19, 2026.
Newsfile (Tue, 17-Nov 9:15 AM ET)
Envoy Medical Earnings Call Highlights Acclaim Progress and Risks
TipRanks (Sat, 14-Nov 10:06 PM ET)
Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Newsfile (Tue, 10-Nov 8:30 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress
Newsfile (Thu, 5-Nov 7:02 AM ET)
Newsfile (Wed, 28-Oct 8:31 AM ET)
Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th
Newsfile (Tue, 27-Oct 8:31 AM ET)
Envoy Medical Announces Reverse Stock Split
Newsfile (Thu, 22-Oct 8:31 AM ET)
Newsfile (Tue, 20-Oct 8:31 AM ET)
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Envoy Medical - Class A trades on the NASDAQ stock market under the symbol COCH.
As of November 19, 2026, COCH stock price declined to $6.70 with 30,821 million shares trading.
COCH has a beta of 0.56, meaning it tends to be less sensitive to market movements. COCH has a correlation of 0.01 to the broad based SPY ETF.
COCH has a market cap of $51.85 million. This is considered a Micro Cap stock.
Last quarter Envoy Medical - Class A reported $66,000 in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-14,000 and exceeded earnings estimates by $.18.
In the last 3 years, COCH traded as high as $114.60 and as low as $3.63.
The top ETF exchange traded funds that COCH belongs to (by Net Assets): VXF, VTI.
COCH has underperformed the market in the last year with a return of -12.5%, while the SPY ETF gained +9.6%. In the last 3 month period, COCH fell short of the market, returning -9.3%, while SPY returned -6.5%. However, in the most recent 2 weeks COCH has outperformed the stock market by returning -5.9%, while SPY returned -6.6%.
COCH support price is $6.24 and resistance is $7.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCH shares will trade within this expected range on the day.